The Role of Stem-Cell Transplant in Multiple Myeloma

Video

Sundar Jagannath, MD, director, Multiple Myeloma Program, Tisch Cancer Institute at Mount Sinai Hospital, discusses the role of stem-cell transplant in the management of multiple myeloma.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results
SC Pembrolizumab Noninferior to IV in NSCLC: Phase 3 Trial Results
Elmariah on the Evolving Role of Fedratinib
Elmariah on the Evolving Role of Fedratinib
Clinical Evaluation of TMLI and PTCy in MRD-Negative AML Transplant
Clinical Evaluation of TMLI and PTCy in MRD-Negative AML Transplant
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
Exploring the Challenges of Radiopharmaceuticals in Prostate Cancer
Exploring the Challenges of Radiopharmaceuticals in Prostate Cancer
Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC
Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC
Elmariah on Maintenance Therapy Posttransplant for Myelofibrosis Relapse and GVHD Prevention
Elmariah on Maintenance Therapy Posttransplant for Myelofibrosis Relapse and GVHD Prevention
Fedratinib Shows Promise in Long-Term MPN Success With Tolerable Toxicity
Fedratinib Shows Promise in Long-Term MPN Success With Tolerable Toxicity
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Related Content
Leighl Covers PALOMA-3 Trial of SC Amivantamab in NSCLC

Leighl Covers PALOMA-3 Trial of SC Amivantamab in NSCLC

Jordyn Sava
April 18th 2025
Article

Natasha Leighl, MD, MMSc, BSc, discussed key findings from the PALOMA-3 trial for a community oncologist audience.

Read More

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Binod Dhakal, MD, MS;Jordyn Sava
June 14th 2024
Podcast

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Listen

Novel Radioenhancer JNJ-1900 Shows Potential Across Cancers

Novel Radioenhancer JNJ-1900 Shows Potential Across Cancers

Jordyn Sava
April 15th 2025
Article

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.

Read More

Advancing Myeloma Treatment With Blood-Based MRD Testing

Advancing Myeloma Treatment With Blood-Based MRD Testing

Jordyn Sava;Ben Derman, MD
February 15th 2024
Podcast

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

COA Advocates for Biomarker Testing Access, Physician Autonomy in Cancer Care

COA Advocates for Biomarker Testing Access, Physician Autonomy in Cancer Care

Jordyn Sava
April 11th 2025
Article

Nicolas Ferreyros discussed central ideas from the Community Oncology Alliance to optimize cancer care in community oncology settings.

Read More

Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

Real-World Study Confirms Teclistamab’s Efficacy in Heavily Pretreated RRMM, Aligning with MajesTEC-1 Findings

Tony Berberabe, MPH
April 11th 2025
Article

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Read More